

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: markspencer

Timestamp: Mon Aug 13 08:24:32 EDT 2007

=====

Application No: 10666291

Version No: 1.0

Input Set:

Output Set:

Started: 2007-08-10 18:27:04.808

Finished: 2007-08-10 18:27:05.491

Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 683 ms

Total Warnings: 15

Total Errors: 0

No. of SeqIDs Defined: 15

Actual SeqID Count: 15

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)

SEQUENCE LISTING

<110> Invitrogen Corporation
Beechem, Joseph
Hagen, David
Johnson, Iain

<120> Antibody complexes and methods for immunolabeling

<130> IVGN 703.1 CIP

<140> 10666291

<141> 2007-08-10

<150> 10/666,291

<151> 2003-09-17

<150> 10/467,550

<151> 2002-10-02

<150> PCT/US02/31416

<151> 2002-10-02

<150> 10/118,204

<151> 2002-04-05

<150> 60/329,068

<151> 2001-10-12

<150> 60/369,418

<151> 2001-04-01

<160> 15

<170> PatentIn version 3.3

<210> 1

<211> 9

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 1

Glu Asn Asp Tyr Ile Asn Ala Ser Leu

1 5

<210> 2

<211> 11

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 2

Asp Ala Asp Glu Tyr Leu Ile Pro Gln Gln Gly
1 5 10

<210> 3

<211> 6

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 3

Asp Ala Asp Glu Tyr Leu
1 5

<210> 4

<211> 5

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 4

Ile Tyr Gly Glu Phe
1 5

<210> 5

<211> 9

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 5

Thr Glu Pro Glu Tyr Gln Pro Gly Glu
1 5

<210> 6

<211> 6

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 6

Asp Tyr Val Pro Met Leu

1 5

<210> 7

<211> 11

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 7

Glu Pro Gln Tyr Glu Glu Ile Pro Ile Tyr Leu

1 5 10

<210> 8

<211> 17

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 8

Glu Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Ser

1 5 10 15

Phe

<210> 9

<211> 13

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 9

Thr Ser Thr Glu Pro Gln Tyr Gln Pro Gly Glu Asn Leu

1 5 10

<210> 10

<211> 12

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 10

Glu Ala Ile Tyr Ala Ala Pro Phe Ala Lys Lys Lys
1 5 10

<210> 11

<211> 9

<212> PRT

<213> Artificial

<220>

<223> phosphotyrosine ligands

<400> 11

Trp Ala Gly Gly Asp Ala Ser Gly Glu
1 5

<210> 12

<211> 12

<212> PRT

<213> Artificial

<220>

<223> ABL Peptide

<400> 12

Glu Ala Ile Tyr Ala Ala Pro Phe Ala Lys Lys Lys
1 5 10

<210> 13

<211> 13

<212> PRT

<213> Artificial

<220>

<223> CSRC Peptide

<400> 13

Thr Ser Thr Glu Pro Gln Tyr Gln Pro Gly Glu Asn Leu
1 5 10

<210> 14

<211> 9

<212> PRT

<213> Artificial

<220>

<223> DSIP Peptide

<400> 14

Trp Ala Gly Gly Asp Ala Ser Gly Glu
1 5

<210> 15

<211> 13

<212> PRT

<213> Artificial

<220>

<223> TYR Peptide

<400> 15

Glu Ala Ile Tyr Ala Ala Pro Phe Ala Lys Lys Lys Cys
1 5 10